Evaluation of overall survival and disease-free survival of adjuvant chemotherapy and hormone therapy in patients with breast cancer

Kamran Roudini; Mehrzad Mirzania; Seyyed Amirhossein Emami; Seyyed Reza Safayi; Ehsan Kamali yazdi; Nasim Zarifi; Masoud  Mortezazadeh; Shima Rafiee; Abbas Mofidi; Mehdi Kashani; Ensieh sadat Mansouri; Mohammad Rasekhi Siahkal mahalleh; Ahmad Khajeh Mehrizi

doi:10.18502/bccr.v14i2.14376

Kamran Roudini Cancer Institute, Imam Khomeini Hospital Complex, Tehran university of Medical Sciences, Tehran, Iran
Mehrzad Mirzania Cancer Institute, Imam Khomeini Hospital Complex, Tehran university of Medical Sciences, Tehran, Iran
Seyyed Amirhossein Emami Cancer Institute, Imam Khomeini Hospital Complex, Tehran university of Medical Sciences, Tehran, Iran
Seyyed Reza Safayi Cancer Institute, Imam Khomeini Hospital Complex, Tehran university of Medical Sciences, Tehran, Iran
Ehsan Kamali yazdi Hematology and Oncology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Science, Tehran, Iran
Nasim Zarifi School of Medicine, Tehran University of Medical Science, Tehran, Iran
Masoud Mortezazadeh Internal Medicine Department, Sina Hospital, Tehran University of Medical Science, Tehran, Iran
Shima Rafiee School of Medicine, Tehran University of Medical Science, Tehran, Iran
Abbas Mofidi School of Medicine, Iran University of Medical Science, Tehran, Iran
Mehdi Kashani School of Medicine, Tehran University of Medical Science, Tehran, Iran
Ensieh sadat Mansouri Internal Medicine Department, Sina Hospital, Tehran University of Medical Science, Tehran, Iran
Mohammad Rasekhi Siahkal mahalleh School of Medicine, Tehran University of Medical Science, Tehran, Iran
Ahmad Khajeh Mehrizi Hematology and Oncology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Science, Tehran, Iran

DOI: https://doi.org/10.18502/bccr.v14i2.14376

Keywords: breast cancer; disease-free survival index; overall survival index

Abstract

Background: This study evaluated the effect of adjuvant chemotherapy and hormone therapy on overall survival and disease-free survival in patients with breast cancer with hormone receptor-positive, HER2-negative tumors without lymph node involvement.

Methods: Breast cancer patients with hormone receptor-positive, HER2-negative, and no lymph node involvement were included in this retrospective cohort study. Patient records were used to collect data on sex, age, time of disease onset, tumor subtype, tumor size, grade, lymphovascular and perineural involvement, ki67, and treatment protocols. Patients were divided into 2 groups: Patients who received both adjuvant chemotherapy and hormonal therapy and patients who received hormonal therapy only. Disease-free survival index (DFS) and overall survival index (OS) were evaluated.

Results: Sixty-seven female patients were enrolled in this study. Of them, 68.2% received both adjuvant chemotherapy and hormonal therapy and 31.6% received hormonal therapy only. During follow-up, recurrences occurred in 8 patients. The 3-year and 5-year DFS were 93.4% and 90%, respectively. The 3-year and 5-year DFS was 94% and 92%, respectively, in patients who received both adjuvant chemotherapy and hormonal therapy, and 91% and 85%, respectively, in patients who received hormonal therapy. None of the factors studied affected the 3-year and 5-year DFS. The 3-year and 5-year DFS OS were 98.6% and 96.9%, respectively

Conclusion: Adjuvant chemotherapy in patients with breast cancer with hormone receptor-positive, HER2-negative, and no lymph node involvement compared with similar patients receiving hormone therapy alone had no significant difference in disease-free survival index and overall survival index.